Question 1

What has been measured for CJC-1295 and ipamorelin together?

Accepted Answer

One experiment, in mice. A 2026 primer written for orthopaedic and sports medicine physicians assessed the two as a unit, naming CJC-1295 + ipamorelin among the key peptides evaluated. Its finding was that CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies. Two details decide what that is worth. Maximum tetanic tension is the peak force a stimulated muscle can put out on a lab bench, which is not strength as anyone experiences it. And glucocorticoid-induced muscle loss means the animals were being wasted by a steroid, so the test asked whether the pair defends muscle under attack. Whether it adds muscle to a healthy adult is a different question, and no trial among the research behind this page has asked it.

Question 2

Have CJC-1295 and ipamorelin been compared head to head?

Accepted Answer

No. No study among the research behind this page has given CJC-1295 and ipamorelin to the same participants and measured which one did more, so this page will not name a winner. That ranking does not exist in the literature, and inventing one would mean setting a hormone curve in healthy adults beside a force reading in mice. The two have been studied as a pair, rather than against each other. A 2026 review of peptides in ageing lists combination therapy effects among the significant knowledge gaps for this class. A 2026 structured review arrives at the same place from the clinical side, recording that growth hormone axis secretagogues such as CJC-1295, ipamorelin and tesamorelin remain investigational, with uncertain safety profiles and product quality concerns. The absence of a comparison is the honest answer here, and it is also the most useful one.

Question 3

What is ipamorelin, as far as the published sources go?

Accepted Answer

Less than most readers assume, and ipamorelin now has a page of its own on this site. A 2026 critical review files it as a growth hormone secretagogue, a separate class from the growth hormone-releasing hormone analogues where CJC-1295 sits. A 2026 review of this axis puts ipamorelin alongside GHRP-2, GHRP-6 and hexarelin in that secretagogue group. A 2026 orthopaedic review describes what the class is thought to do, saying that growth hormone secretagogues like ipamorelin, CJC-1295, tesamorelin, sermorelin, and AOD-9604 activate IGF-1 signaling and satellite cell repair. The same review records a current lack of clinical trials. So ipamorelin reaches the same gland by a different route, and what it does in a person on its own is not something the cited literature settles.

Question 4

Can you get CJC-1295 and ipamorelin from a compounding pharmacy?

Accepted Answer

A compounding pharmacy makes a medicine to order rather than in batches. Such pharmacies have made the combination, and the public evidence for that is the FDA enforcement record. One recall covers CJC-1295 4MG/IPAMORELIN 4MG VIAL 4MG/4MG INJECTABLE from Talon Compounding Pharmacy, withdrawn for lack of assurance of sterility. A recall is a firm pulling stock back off the market. Another covers CJC-1295 2000 mcg/Ipamorelin 2000 mcg/mL Inj. in 2 mL vial, pulled for lack of sterility assurance. Those records establish that the combination was dispensed in the United States and that batches of it were recalled. They do not establish that any pharmacy can supply it today, and they say nothing about whether either molecule does anything. A 2026 review of this axis records the absence of regulatory approval for physique- or performance-related indications, which is the backdrop to every one of these records.

Question 5

How much do CJC-1295 and ipamorelin cost per month?

Accepted Answer

No source cited on this page gives a price, and that is a real limit rather than an oversight. Prices for unapproved compounds are set by sellers and are not published in the scientific literature, so any figure put here would be invented. What the record does establish is why a price on its own would tell you very little. A 2026 critical review reports that the largely unregulated supply chain exacerbates these dangers, as products are often mislabeled or contaminated. A 2026 structured review names product quality concerns for this class in the same sentence as uncertain safety profiles. Two vials at the same price need not hold the same thing, and nothing in the cited record lets a buyer tell them apart from the outside.

Question 6

How long does one vial of CJC-1295 and ipamorelin last?

Accepted Answer

That depends on an amount per use that no study among the research behind this page establishes. A 2026 primer puts it flatly: information regarding the indications, dosing, frequency, and duration of treatment remains unknown. Without a figure on the bottom of that division, the answer is arithmetic with a number missing. What the FDA records do supply is the size of the containers that reached patients. One recalled item was a CJC-1295 4MG/IPAMORELIN 4MG VIAL, and another was CJC-1295 2000 mcg/Ipamorelin 2000 mcg/mL Inj. in 2 mL vial. Those are packaging facts rather than protocols, and they are the only part of this question that can be answered from a regulatory record instead of a forum thread.

Question 7

How long does it take to see results from CJC-1295 and ipamorelin?

Accepted Answer

No trial among the research behind this page has measured a result in a person given the combination, so there is no onset to report, and the nearest timing data belongs to CJC-1295 on its own. All of that evidence is biochemical rather than clinical. In healthy adults, a single injection brought dose-dependent increases in mean plasma growth hormone by 2- to 10-fold for 6 days or more, and the estimated half-life of CJC-1295 was 5.8 to 8.1 days. That is a hormone concentration curve rather than an outcome, and the main CJC-1295 page sets out the complete time course. The animal experiment on the combination read muscle force once, at the conclusion, rather than tracking a weekly progression. So a documented timeline exists for a blood marker, and none exists for anything a person would actually notice.

Question 8

Is CJC-1295 and ipamorelin therapy good for you?

Accepted Answer

That is a question about your own decision, and we do not answer those. Judging a study is our job. Judging what you do next is not. What we can report is where the authors who read this evidence landed. A 2026 primer concluded that significant research regarding the safety and efficacy of these therapeutic methods is required before definitive recommendations can be made to patients. A 2026 structured review concluded that injectable peptides for sports medicine remain largely experimental. A 2026 review in Sports Medicine states that rigorous human safety data are scarce, and there is potential for serious harm. The same review digs into the placebo effect as a mediator of peptide efficacy, and how social media amplifies this effect. That last point is worth weighing against any account built on how somebody felt.

Question 9

CJC-1295 vs MK-677: what has been measured?

Accepted Answer

In the research behind this page, they appear in the same review and have not been set against each other. A 2026 scoping review examined 6 emerging peptides, naming BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu. It reports them one at a time rather than head to head, and found that 67% of identified publications utilized preclinical animal models. The one line that separates them concerns harm. Some peptides such as MK-677 were associated with significant risks including congestive heart failure, and significant heterogeneity existed in dosing and route of administration. Read what that is. It is a documented risk attached to one compound inside a review covering both, rather than a finding that CJC-1295 carries less risk, which no study among the research behind this page has tested.

Question 10

CJC-1295 vs IGF-1 LR3: how do they differ?

Accepted Answer

They sit at different points of the same chain, and no study among the research behind this page has compared them. A 2026 review of this axis groups CJC-1295 with the growth hormone-releasing hormone analogues and lists insulin-like growth factor-1 (IGF-1) analogues (e.g., pegylated mechano growth factor (PEG-MGF), IGF-1 Long R3 (IGF-1 LR3)) as a separate category. Doping-control literature keeps the same split, with a 2012 method paper purifying growth hormone releasing hormone (GH-RH(1-29)) and CJC-1295 (GH-RH analogue), LongR(3)-IGF-1 and IFG-1 as distinct targets. The practical difference is where each one enters. CJC-1295 asks the pituitary for growth hormone, while the IGF-1 analogues supply the downstream messenger directly. That is a difference in mechanism rather than in evidence, because neither has been measured against the other in a person.

Question 11

Is the CJC-1295, ipamorelin and IGF-1 LR3 stack studied?

Accepted Answer

No study among the research behind this page looks at those three together, in people or in mice. A 2026 review of this axis faces the practice without backing it, naming the uncertainty surrounding product composition, dose, and stacking practices in unregulated supply chains. Read that as what it is. It is a note that people stack, not a finding that stacking does anything. A 2026 critical review makes the same point about the evidence base. Most published studies examine therapeutic applications under controlled dosing regimens, not the supraphysiological or combined protocols common in bodybuilding. What gets studied and what gets stacked are two different things. A 2026 review of peptides in ageing lists combination therapy effects among its knowledge gaps. So the gap is the finding: no source we cite has measured a three-way stack against any of its parts.

Question 12

CJC-1295 vs tesamorelin: what separates them?

Accepted Answer

One of the two finished its development, and the other did not. A 2026 primer records that tesamorelin is approved for treating HIV-associated lipodystrophy, a change in how the body stores fat, while adding that it has no supporting orthopaedic evidence. CJC-1295 carries no approval at all. The two are close chemical relatives. Doping-control papers list them side by side as growth hormone releasing hormones (sermorelin, CJC-1293, CJC-1295, tesamorelin), and a 2021 paper counts them among four of the larger GHRH synthetic analogs. So what splits them is a file at a regulator, rather than a difference in the molecules. On one side sits an approval for one named condition. On the other sits a trial that stopped. No study among the research behind this page has put the two in the same room.

Question 13

CJC-1295 and ipamorelin versus HGH: what is the difference?

Accepted Answer

Growth hormone is the hormone itself, while these two ask the body to release its own. A 2019 paper describes CJC-1295 as a peptide-based drug that stimulates the production of growth hormone from the pituitary gland, which is one step upstream of injecting growth hormone. A 2026 review frames the whole category as unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. Doping-control work keeps growth hormone releasing hormone and its analogues as a separate class of target from growth hormone. What no cited source supplies is a trial comparing either compound with growth hormone in the same participants. The mechanisms differ in a way anyone can describe, and the outcomes have never been measured against each other in any study among the sources assembled for this page.

Question 14

Are CJC-1295 and ipamorelin used with retatrutide?

Accepted Answer

No published source cited on this page looks at retatrutide alongside CJC-1295 or ipamorelin. That is worth saying plainly, rather than filling the space with a guess. The work behind this page concerns the growth hormone axis, which a 2026 review sums up as unregulated peptides intended to modulate the growth hormone-insulin-like growth factor-1 (GH-IGF-1) axis. A 2026 review of peptides in ageing names combination therapy effects as one of the significant knowledge gaps in the field, and this pairing is one of them. So there is no reported interaction, no reported result, and nothing measured. A combination no study among the research behind this page has studied has nothing to report, in either direction.

Question 15

How does the strength of the evidence compare?

Accepted Answer

Unevenly, and the gap between them is the most useful thing on this page. CJC-1295 is the only compound named here with randomised human data of any kind. That means two randomized, placebo-controlled, double-blind, ascending dose trials in healthy adults, which tracked hormone levels rather than outcomes. The pair with ipamorelin has one animal result. MK-677, IGF-1 LR3 and the three-way stack have no comparison at all. A 2026 review of this axis maps that spread, stratifying peptides into evidence tiers from regulatory-grade randomized trial data to a complete absence of human studies. A 2026 scoping review sets the ceiling, concluding that the claimed benefits for musculoskeletal recovery and performance remain unsubstantiated by current human trials. None of this is near settled. The gaps between these compounds are gaps in how much anyone has looked.

CJC-1295 comparisons and stacks